Norman Cousins LectureGlia as the “bad guys”: Implications for improving clinical pain control and the clinical utility of opioids
Section snippets
Overview
Within just the past decade, there has been increasing recognition that glia are far more than simply “housekeepers” for neurons, providing neurochemical precursors and energy sources to neurons, regulating extracellular ion concentrations, removing debris, and so on. It is now known that glia also importantly contribute to fever, alterations in sleep, disruption of learning and memory, as well as to neuroinflammatory/neurodegenerative conditions such as ischemia/stroke, Alzheimer’s disease,
Glia
The work to be reviewed focuses on two types of glial cells, astrocytes and microglia. When these cells become activated, they (a) upregulate cell-type specific activation markers (allowing this reflection of activation to be easily visualized using immunohistochemistry) and (b) release a variety of substances (e.g., proinflammatory cytokines, chemokines, ATP, excitatory amino acids, nitric oxide, etc.) that enhance pain by increasing the excitability of nearby neurons. Microglia and astrocytes
Glial dysregulation of pain
Under normal situations, when spinal glia are in their basal state, they have little-to-no influence on pain responsivity (Fig. 1). Various drugs that suppress glial function have consistently failed to alter responsivity to heat or mechanical stimuli in normal animals (Hashizume et al., 2000, Ledeboer et al., 2005, Meller et al., 1994). While data from knockouts reveal reductions in basal pain responsivity in adult mice with disrupted IL-1 signaling, these changes appear related to
How do spinal glia “know” to become activated?
A key question is: “What is released in spinal cord, as a result of inflammation/trauma in the periphery that “tells” glia to activate?” Increasing focus is being directed at microglia as the “trigger”, as the initiator of pain facilitation. Microglia are exquisitely sensitive to signals of “not self” or “not normal”, leading them to be far more reactive in responding to CNS challenges than other candidate cell types (Kreutzberg, 1996). Similarly, spinal cord microglia are the earliest glial
How can glial activation affect neuronal activity?
It is remarkable that diverse enhanced pain states are all suppressed by inhibiting glial function (Watkins and Maier, 2003). However, this does not provide insight into what the glial products are that enhance pain. This issue is, in part, relatively simple and, in part, complicated. “Relatively simple” refers to situations in which pain enhancement can be clearly linked to the release of classical glial products, such as proinflammatory cytokines. “Relatively” simple must be kept in mind
Non-neuronal cells beyond glia: might they also contribute to pain enhancement?
Before leaving the topic of pain facilitation, it is worth noting that astrocytes and microglia may well not be the only non-neuronal cell types capable of enhancing pain in spinal cord. As noted above (Section 2), other cell types in spinal cord can generate proinflammatory cytokines and other neuroexcitatory substances, such as fibroblasts, perivascular macrophages, dendritic cells, and endothelial cells. The potential involvement of such cells in pain facilitation has not yet been explored.
Responses of glia to chronic opioids: contribution to morphine tolerance and withdrawal-induced pain enhancement
A strong case has been made that the mechanisms underlying neuropathic pain and morphine tolerance are strikingly similar (Mayer et al., 1999). Given the strength of evidence implicating glia in pain facilitation, including neuropathic pain, it was natural to extend this question to whether glia were similarly involved in the production of morphine tolerance. As will be reviewed below, it is now clear that this is indeed the case (Watkins et al., 2005).
The first report linking glia to morphine
How can glial activation affect neuronal responses to opioids?
This issue is obviously related to the parallel discussion in Section 5, above. As we have shown that proinflammatory cytokines are also released in response to morphine (Johnston et al., 2004) the reader is referred back to the prior section for review of issues that are equally pertinent here. Beyond what has already been discussed, there are additional mechanisms that may come into play when exploring how glial activation may suppress responsivity to morphine.
The first is that opioids can
Implications for clinical pain control
The potential implications of glial involvement in the dysregulation of pain and opioid actions are vast. Regarding pain, the fundamental, inescapable fact is that present treatments for chronic pain fail. The drugs currently used to treat clinical pain problems were all developed to target neurons, prior to the discovery that glia regulate pain. Present knowledge of glial regulation of pain derives from many different laboratories using many different animal and in vitro models, and equally as
References (135)
Chemokines, chemokine receptors and pain
Trends Immunol.
(2005)- et al.
The N-methyl-d-aspartate (NMDA) receptor is postsynaptic to substance P-containing axon terminals in the rat superficial dorsal horn
Brain Res.
(1997) - et al.
Central neuron-glial and glial-glial interations following axon injury
Prog. Neurobiol.
(1998) - et al.
Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS
Pain
(2005) - et al.
Functional expression of CXCR3 in cultured mouse and human astrocytes and microglia
Neuroscience
(2002) - et al.
Activation of p38 mitogen-activated protein kinase in spinal microglia mediates morphine antinociceptive tolerance
Brain Res.
(2006) - et al.
The distribution of receptors for the pro-inflammatory cytokines interleukin (IL)-6 and IL-8 in the developing human fetus
Early Hum. Dev.
(2000) Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity
Eur. J. Pharmacol.
(2004)- et al.
Tumor necrosis factor alpha increases cytosolic calcium responses to AMPA and KCl in primary cultures of rat hippocampal neurons
Brain Res.
(2003) - et al.
TNF-alpha increases the frequency of spontaneous miniature synaptic currents in cultured rat hippocampal neurons
Brain Res.
(1994)
Central administration of methotrexate reduces mechanical allodynia in an animal model of radiculopathy/sciatica
Pain
HIV-1 gp120 stimulates proinflammatory cytokine-mediated pathological pain via activation of nitric oxide synthase-I (nNOS)
Pain
Immunocytochemical localization of TNF type 1 and type 2 receptors in the rat spinal cord
Brain Res.
Interleukin-1alphabeta gene-deficient mice show reduced nociceptive sensitivity in models of inflammatory and neuropathic pain but not post-operative pain
Behav. Brain Res.
Relationship between 4,5-epoxymorphinan structure and in vitro modulation of cell proliferation
Eur. J. Pharmacol.
(S)-(+)-methadone is more immunosuppressive than the potent analgesic (R)-(–)-methadone
Int. Immunopharmacol.
Characterisation of the in vitro modulation of splenocyte proliferation by non-4,5-epoxymorphinan opioids
Int. Immunopharmacol.
The function of microglia through purinergic receptors: neuropathic pain and cytokine release
Pharmacol. Ther.
Acute and conditioned sickness reduces morphine analgesia
Behav. Brain Res.
Inhibition of morphine analgesia by LPS: role of opioid and NMDA receptors and spinal glia
Behav. Brain Res.
Microglia: a sensor for pathological events in the CNS
Trends Neurosci.
Cytokine involvement in dynorphin-induced allodynia
Pain
Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation
Pain
Spinal cord glia and interleukin-1 do not appear to mediate persistent allodynia induced by intramuscular acidic saline in rats
J. Pain
Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain
J. Pain
Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy
Pain
Immune and glial cell factors as pain mediators and modulators
Exp. Neurol.
The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat
Neuropharmacology
Nitric oxide synergistically potentiates interleukin-1 beta-induced increase of cyclooxygenase-2 mRNA levels, resulting in the facilitation of substance P release from primary afferent neurons: involvement of cGMP-independent mechanisms
Neuropharmacology
Spinal glial activation contributes to postoperative mechanical hypersensitivity in the rat
J. Pain.
Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: central nervous system effects
Cytokine
Intracerebroventricular injection of interleukin-1b enhances nociceptive neuronal responses of the trigeminal nucleus caudalis in rats
Brain Res.
Cytokine and chemokine inter-regulation in the inflamed or injured CNS
Brain Res. Brain Res. Rev.
Fractalkine and minocycline alter neuronal acivity in the spinal cord dorsal horn
FEBS Lett.
Communication between astrocytes and neurons: a complex language
J. Physiol.
Immunohistochemical localisation of macrophages and microglia in the adult and developing mouse brain
Neurosci.
Symptomatic lumbar spinal arachnoiditis: fact or fallacy?
J. Clin. Neurosci.
Like cops on the beat: the active role of resting microglia
Trends Neurosci.
Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat
Eur. J. Pain
Opioid use in the treatment of chronic pain: assessment of addiction
J. Pain Symp. Manage.
Interleukin-1 antagonizes morphine analgesia and underlies morphine tolerance
Pain
Anterograde TNF alpha transport from rat dorsal root ganglion to spinal cord and injured sciatic nerve
Neurosci. Lett.
The involvement of glial cells in the development of morphine tolerance
Neurosci. Res.
Potent effect of interleukin-1 beta to evoke ATP and adenosine release from rat hippocampal slices
J. Neuroimmunol.
Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2
Proc. Natl. Acad. Sci. USA
Viewing chemokines as a third major system of communication in the brain
Aaps J.
Follow-up study of 105 patients who left treatment
Activation of group III metabotropic glutamate receptors inhibits the production of RANTES in glial cell cultures
J. Neurosci.
Priming effect of morphine on the production of tumor necrosis factor-alpha by microglia: implications in respiratory burst activity and human immunodeficiency virus-1 expression
J. Pharmacol. Exp. Ther.
Cited by (301)
Common mechanisms involved in lung cancer and depression: The dominant role of interleukin-6-IDO pathway in the lung-brain axis
2023, Journal of Affective Disorders ReportsEffect of pharmacological modulation of the kynurenine pathway on pain-related behavior and opioid analgesia in a mouse model of neuropathic pain
2023, Toxicology and Applied PharmacologyCrosstalk between Mu-Opioid receptors and neuroinflammation: Consequences for drug addiction and pain
2023, Neuroscience and Biobehavioral Reviews
- 1
Linda R. Watkins was the recipient of the 2006 Norman Cousins Award.